Holen Sie sich die Stockscreener-App
38.25
3.38%
1.25
Vorhandelsmarkt:
38.20
-0.05
-0.13%
Schlusskurs vom Vortag:
$37.00
Offen:
$36.985
24-Stunden-Volumen:
543.62K
Relative Volume:
0.58
Marktkapitalisierung:
$2.20B
Einnahmen:
$772.53M
Nettoeinkommen (Verlust:
$180.90M
KGV:
12.33
EPS:
3.1024
Netto-Cashflow:
$258.73M
1W Leistung:
+7.56%
1M Leistung:
+24.51%
6M Leistung:
+8.79%
1J Leistung:
+9.54%
1-Tages-Spanne:
$36.86
$38.80
1-Wochen-Bereich:
$35.14
$38.80
52-Wochen-Spanne:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
38.25 | 2.13B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockJuly 2025 Institutional & High Accuracy Buy Signal Tips - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences to present Dravet syndrome trial data at AES meeting - Investing.com Canada
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound - Yahoo Finance
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors - Yahoo Finance
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial - Yahoo Finance
A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results - simplywall.st
Harmony Biosciences to present Dravet syndrome trial data at AES meeting By Investing.com - Investing.com South Africa
Harmony Biosciences (Nasdaq: HRMY) to share new EPX-100 Dravet data at 2025 AES - Stock Titan
Prudential Financial Inc. Has $4.79 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastPrice Momentum Alerts & Fast Growing Capital Gains - earlytimes.in
Mizuho Maintains Harmony Biosciences Holdings (HRMY) Outperform Recommendation - Nasdaq
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress By Investing.com - Investing.com South Africa
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com Australia
HRMY Upgraded by Mizuho: Price Target Raised to $46 | HRMY Stock News - GuruFocus
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho - StreetInsider
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MyChesCo
Geode Capital Management LLC Raises Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
(HRMY) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Harmony Biosciences Holdings Inc. stock deliver surprise earnings beatEarnings Overview Summary & Verified Swing Trading Watchlist - BỘ NỘI VỤ
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results - Investing.com Canada
Harmony Biosciences stock reaffirmed at Outperform by Oppenheimer - Investing.com Canada
HC Wainwright & Co. Reiterates Harmony Biosciences Holdings (HRMY) Buy Recommendation - Nasdaq
Harmony Biosciences reports positive results for pitolisant GR formulation By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for HRMY, Maintains Price Ta - GuruFocus
Needham Reiterates Buy Rating on HRMY with Unchanged Price Targe - GuruFocus
Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results - marketscreener.com
Harmony Biosciences (HRMY) Advances with New Pitolisant Formulat - GuruFocus
Harmony Biosciences reports positive results for pitolisant GR formulation - Investing.com
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation - Lelezard
Harmony Biosciences reports positive pitolisant bioequivalence study results - StreetInsider
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet - StreetInsider
CFO Kapadia Files To Sell 3,427 Of Harmony Biosciences Holdings Inc [HRMY] - TradingView
Is Harmony Biosciences Holdings Inc. stock supported by strong cash flows2025 Technical Overview & Smart Investment Allocation Tips - newser.com
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb - simplywall.st
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence - BioSpace
What insider trading reveals about Harmony Biosciences Holdings Inc. stockEarnings Growth Report & Low Risk Entry Point Guides - newser.com
Harmony Advances First Human Study of Orexin 2 Agonist - Sleep Review
Why Harmony Biosciences Holdings Inc. stock is favored by top institutionsInsider Buying & Safe Capital Investment Plans - newser.com
Why Harmony Biosciences Holdings Inc. stock could benefit from AI revolution - newser.com
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):